MedTrace Logo

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

NCT03030222 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-12-09

Study results available
· View outcomes & findings →

Summary

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device (a wireless hemodynamic monitoring system) implanted for non-study related clinical reasons.

Conditions

Interventions

DRUG

Empagliflozin 10 mg Tab

Empagliflozin 10 mg Tab

DRUG

Placebo Oral Tablet

Empagliflozin matching placebo

Sponsors & Collaborators

  • Saint Luke's Health System

    lead OTHER

Principal Investigators

  • Mikhail Kosiborod, MD · Saint Luke's Mid America Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
119 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-05
Primary Completion
2020-03-10
Completion
2020-03-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03030222 on ClinicalTrials.gov